
Senti Biosciences (SNTI) Stock
Small cap biotech developing programmable cell therapies for diseases. Here's the price, business snapshot, and what's worth knowing about Senti Biosciences in November 2026.
Senti Biosciences (SNTI) is a synthetic biology company developing programmable cell therapies and biologics. Using a proprietary genetic-circuit platform, the company aims to design cells that respond selectively in the body, with potential applications in oncology and inflammatory disease. The business is early‑stage and largely preclinical; progress depends on R&D milestones, partnerships and future financing. With a market capitalisation of about $53.6m, Senti is a small-cap biotech and can be volatile — clinical setbacks, regulatory hurdles and funding needs may materially affect the share price. Investors should monitor pipeline updates, cash runway, partner deals and regulatory progress. This summary is for general educational purposes only and does not constitute personalised investment advice. Biotech investments carry high risk and it is sensible to consider diversification and whether this fits your risk tolerance before investing.
Senti Biosciences (SNTI) Stock Forecast
Analyst price target, next 12 months
$13.50
+9242.6% vs today's $0.14
Price range over the last 12 months
Close to its 12-month low
Analysts covering Senti Biosciences have a consensus 12-month target of $13.50, above the current price of $0.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 16 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Senti Biosciences stock, with a target price of $13.5 indicating strong growth potential.
Financial Health
Senti Biosciences is struggling with very low revenue and limited cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage biotech growth
Pipeline progress and clinical milestones can move the stock, though outcomes are uncertain and future capital raises may dilute shareholders.
Platform innovation focus
Programmable genetic circuits aim to improve therapeutic precision, but technological and regulatory hurdles mean success is not guaranteed.
Partnerships and funding
Collaborations and financing often drive development pace; watch cash runway and deal announcements as key signals of momentum.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.